《生物医学新技术临床研究和临床转化应用管理条例》实施背景下输血医学科主动承接细胞与基因治疗的机遇、定位与发展路径

陈立力 ,  张进进 ,  张勇刚 ,  邢颜超 ,  余佳

中国输血杂志 ›› 2026, Vol. 39 ›› Issue (7) : 832 -839.

PDF (1272KB)
中国输血杂志 ›› 2026, Vol. 39 ›› Issue (7) : 832 -839. DOI: 10.13303/j.cjbt.issn.1004-549x.2026.07.003
专家述评

《生物医学新技术临床研究和临床转化应用管理条例》实施背景下输血医学科主动承接细胞与基因治疗的机遇、定位与发展路径

作者信息 +

Opportunities, positioning, and development pathways for the Department of Transfusion Medicine to proactively undertake cell and gene therapy under the Regulations on the Clinical Research and Translation of New Biomedical Technologies

Author information +
文章历史 +
PDF (1302K)

摘要

国务院令第818号《生物医学新技术临床研究和临床转化应用管理条例》(以下简称《条例》)的正式施行,标志着我国细胞与基因治疗(cell and gene therapy,CGT)等生物医学新技术领域进入法治化、规范化、全链条监管的新阶段,这将对输血医学学科发展产生深远影响。本文以《条例》确立的核心监管制度为框架,结合输血医学在全链条质量控制、细胞制备与处置、伦理合规审查及临床转化实践中的长期积累,系统梳理输血医学与CGT在技术流程、质控逻辑及管理体系上的高度契合性,阐明输血医学科主动承接CGT领域的学科优势,同时剖析当前科室面临的现实短板与业务转型瓶颈。依托现有体系基础,输血医学科可发展为院内CGT全过程质量控制平台与临床转化枢纽,但须应对合规责任加重、专业技术平台建设滞后、复合型人才储备不足、临床研究与转化标准趋严等诸多挑战。《条例》为输血医学科突破传统单一血液保障职能、构建“血液保障+细胞治疗”协同发展模式提供了法治依据与政策支撑。输血医学科应对标监管要求,健全全流程合规体系、升级技术平台、培养复合型人才,实现向生物治疗核心支撑科室的转型发展。

Abstract

The official implementation of the Regulations on Clinical Research and Translation of New Biomedical Technologies (State Council Decree No. 818, hereinafter referred to as the "Regulations") marks a new stage of legal governance, standardization, and whole-chain regulation for emerging biomedical fields such as cell and gene therapy (CGT) in China, exerting a profound impact on the development of transfusion medicine as a discipline. Within the framework of the core regulatory systems established by the Regulations, and drawing upon the extensive experience of transfusion medicine in comprehensive quality control, cell processing and handling, ethical compliance, and clinical translation, this study systematically elucidates the intrinsic alignment between transfusion medicine and CGT with respect to technical workflows, quality control rationale, and management systems. It further clarifies the discipline-specific advantages of the department of transfusion medicine to proactively undertake CGT engagement, while analyzing current shortcomings and transformational bottlenecks. By leveraging the existing institutional framework, the department of transfusion medicine is well positioned to evolve into a core platform for whole-process quality control and a pivotal hub for in-hospital clinical translation of CGT. However, this transformation must concurrently address multiple challenges, including heightened compliance responsibilities, lagging technical infrastructure, a shortage of interdisciplinary talent, and increasingly stringent standards for clinical research and translation. The Regulations provide a legal basis and policy support for the department of transfusion medicine to transcend its traditional, singular function of blood safety assurance and establish a synergistic development model integrating blood safety and cell therapy. Therefore, the department of transfusion medicine should proactively align with regulatory requirements, refine whole-process compliance systems, upgrade technical platforms, and cultivate interdisciplinary professionals to achieve high-quality transformative development as a core supporting discipline for biotherapy.

关键词

生物医学新技术 / 输血医学 / 细胞与基因治疗 / 质量控制

Key words

new biomedical technologies / transfusion medicine / cell and gene therapy / quality control

引用本文

引用格式 ▾
陈立力,张进进,张勇刚,邢颜超,余佳. 《生物医学新技术临床研究和临床转化应用管理条例》实施背景下输血医学科主动承接细胞与基因治疗的机遇、定位与发展路径[J]. 中国输血杂志, 2026, 39(7): 832-839 DOI:10.13303/j.cjbt.issn.1004-549x.2026.07.003

登录浏览全文

4963

注册一个新账户 忘记密码

参考文献

[1]

中华人民共和国国务院. 生物医学新技术临床研究和临床转化应用管理条例:国务院令第818号[S].2025-09-28.

[2]

State Council of the People′s Republic of China. Decree of the State Council No. 818:Regulations on the administration of clinical research and clinical translation and application of biomedical new technologies[S].2025-09-28.

[3]

YI S, WU C Y, MCINTOSH A, et al. Cell and gene therapy: transforming treatment paradigms for patient-centric care[J].Clin Transl Sci, 2025, 18(12): e70430.

[4]

KIRKEY A, MAIN H, CARPENTR M. Pluripotent stem-cell-derived therapies in clinical trial:a 2025 update[J].Cell Stem Cell, 2025, 32(1): 10-37.

[5]

FDA/CBER. Vaccines, blood & biologics[EB/OL]. (2026-01-12)[2026-05-20].https://www.fda.gov/vaccines-blood-biologics.

[6]

AABB. About AABB:history[EB/OL].(2021-10-15)[2026-05-20].https://www.aabb.org/about-aabb/history.

[7]

THE EUROPEAN PARLIAMENT AND THE COUNCIL OF THE EUROPEAN UNION. Regulation(EU) 2024/1938 of the European Parliament and of the Council of 13 June 2024 on standards of quality and safety for substances of human origin intended for human application and repealing Directives 2002/98/EC and 2004/23/EC[EB/OL].(2024-06-13)[2026-05-20].https://eurlex.europa.eu/legal-content/EN/TXT/?uri=CEL-EX%3A32024R1938&qid=1769776682534.

[8]

王鸿捷, 郭永建. 血液机构质量管理规范/良好实践国际协调的现状与启示[J].中国输血杂志, 2026, 39(5): 689-698.

[9]

WANG H J, GUO Y J. Current status and implications of international harmonized good practices for blood establishments[J].Chin J Blood Transfusion, 2026, 39(5): 689-698.

[10]

European Medicines Agency. Advanced therapy medicinal products: overview[EB/OL].(EMA, undated)[2026-05-20].https://www.ema.europa.eu/en/human-regulatory-overview/advanced-therapy-medicinal-products-overview.

[11]

ISBT. ISBT strategic plan 2026-2030[EB/OL].(2026-04-24)[2026-05-20].https://www.isbtweb.org/documents/isbt-strategy-2026-2030.

[12]

国家药品监督管理局食品药品审核查验中心. 细胞治疗产品生产检查指南[S].2025-01-13.

[13]

Center for Food and Drug Inspection of NMPA. Guidelines formanufacturing inspection of cell therapy products[S].2025-01-13.

[14]

关健. 《生物医学新技术临床研究与临床转化应用管理条例》执行挑战与难点[J].中华医学科研管理杂志, 2026, 39(1): 1-4.

[15]

GUAN J. Challenges and difficulties in implementing the Regulation on the Clinical Research and Clinical Translation Practice of New Biomedical Technologies[J].Chin J Med Sci Res Manag, 2026, 39(1): 1-4.

[16]

汤红明. 《生物医学新技术临床研究和临床转化应用管理条例》的深度思考:机遇、挑战及实施路径[J].中华细胞与干细胞杂志(电子版), 2026, 16(1): 56-62.

[17]

TANG H M. A deep thinking on the Regulations on the Clinical Research and Clinical Translation Application of New Biomedical Technologies:opportunities, challenges and implementation pathways[J].Chin J Cell Stem Cell, 2026, 16(1): 56-62.

基金资助

新疆维吾尔自治区自然科学基金面上项目(2025D01C246)

AI Summary AI Mindmap
PDF (1272KB)

0

访问

0

被引

详细

导航
相关文章

AI思维导图

/

〈 〉